|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BATF2 |
Gene summary for BATF2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BATF2 | Gene ID | 116071 |
| Gene name | basic leucine zipper ATF-like transcription factor 2 | |
| Gene Alias | SARI | |
| Cytomap | 11q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0001562 | UniProtAcc | B4DV37 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 116071 | BATF2 | HCC1_Meng | Human | Liver | HCC | 1.49e-05 | 2.47e-03 | 0.0246 |
| 116071 | BATF2 | S027 | Human | Liver | HCC | 8.20e-04 | 6.42e-01 | 0.2446 |
| 116071 | BATF2 | S028 | Human | Liver | HCC | 2.12e-09 | 5.71e-01 | 0.2503 |
| 116071 | BATF2 | S029 | Human | Liver | HCC | 7.73e-11 | 5.64e-01 | 0.2581 |
| 116071 | BATF2 | C04 | Human | Oral cavity | OSCC | 3.41e-02 | 1.71e-01 | 0.2633 |
| 116071 | BATF2 | C21 | Human | Oral cavity | OSCC | 3.66e-18 | 5.53e-01 | 0.2678 |
| 116071 | BATF2 | C30 | Human | Oral cavity | OSCC | 8.80e-22 | 7.95e-01 | 0.3055 |
| 116071 | BATF2 | C46 | Human | Oral cavity | OSCC | 5.97e-07 | 1.99e-01 | 0.1673 |
| 116071 | BATF2 | LN46 | Human | Oral cavity | OSCC | 9.20e-04 | 3.08e-01 | 0.1666 |
| 116071 | BATF2 | SYSMH2 | Human | Oral cavity | OSCC | 8.17e-12 | 3.14e-01 | 0.2326 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003009922 | Liver | HCC | myeloid cell differentiation | 200/7958 | 381/18723 | 4.64e-05 | 4.49e-04 | 200 |
| GO:003009920 | Oral cavity | OSCC | myeloid cell differentiation | 213/7305 | 381/18723 | 1.24e-11 | 4.42e-10 | 213 |
| GO:000257310 | Oral cavity | OSCC | myeloid leukocyte differentiation | 119/7305 | 208/18723 | 7.29e-08 | 1.29e-06 | 119 |
| GO:19031316 | Oral cavity | OSCC | mononuclear cell differentiation | 210/7305 | 426/18723 | 8.44e-06 | 9.02e-05 | 210 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05235 | Oral cavity | OSCC | PD-L1 expression and PD-1 checkpoint pathway in cancer | 56/3704 | 89/8465 | 1.97e-04 | 6.55e-04 | 3.33e-04 | 56 |
| hsa052351 | Oral cavity | OSCC | PD-L1 expression and PD-1 checkpoint pathway in cancer | 56/3704 | 89/8465 | 1.97e-04 | 6.55e-04 | 3.33e-04 | 56 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BATF2 | SNV | Missense_Mutation | novel | c.410N>T | p.Ser137Phe | p.S137F | Q8N1L9 | protein_coding | deleterious(0.01) | possibly_damaging(0.496) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| BATF2 | SNV | Missense_Mutation | rs564496581 | c.22N>A | p.Gly8Arg | p.G8R | Q8N1L9 | protein_coding | tolerated(0.06) | benign(0.169) | TCGA-Q1-A5R1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| BATF2 | SNV | Missense_Mutation | rs373876947 | c.352C>T | p.Arg118Trp | p.R118W | Q8N1L9 | protein_coding | deleterious(0) | benign(0.003) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BATF2 | SNV | Missense_Mutation | c.617N>T | p.Pro206Leu | p.P206L | Q8N1L9 | protein_coding | tolerated(0.49) | benign(0) | TCGA-AA-3848-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| BATF2 | SNV | Missense_Mutation | rs377505280 | c.701N>A | p.Arg234His | p.R234H | Q8N1L9 | protein_coding | tolerated(0.55) | benign(0) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BATF2 | SNV | Missense_Mutation | c.643A>G | p.Thr215Ala | p.T215A | Q8N1L9 | protein_coding | tolerated(0.21) | benign(0) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| BATF2 | SNV | Missense_Mutation | c.233A>G | p.His78Arg | p.H78R | Q8N1L9 | protein_coding | tolerated(0.33) | benign(0.133) | TCGA-D5-6927-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| BATF2 | SNV | Missense_Mutation | novel | c.410C>A | p.Ser137Tyr | p.S137Y | Q8N1L9 | protein_coding | tolerated(0.08) | benign(0.056) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| BATF2 | SNV | Missense_Mutation | c.179N>T | p.Arg60Leu | p.R60L | Q8N1L9 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-EP-A3RK-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
| BATF2 | SNV | Missense_Mutation | c.586N>A | p.Gln196Lys | p.Q196K | Q8N1L9 | protein_coding | deleterious(0.01) | benign(0.018) | TCGA-55-A490-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |